| 1 | Articulating the JACC Journals’ Direction in Times of Global Change | 2.6 | 0 | Citations (PDF) |
| 2 | Does Adiponectin Inform Cardiovascular Risk in Older Adults? | 1.5 | 0 | Citations (PDF) |
| 3 | Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies | 4.9 | 4 | Citations (PDF) |
| 4 | Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping | 4.9 | 7 | Citations (PDF) |
| 5 | Early Recognition of Clinical Trajectories Using Machine Learning in Hospitalized Heart Failure Patients | 1.5 | 1 | Citations (PDF) |
| 6 | Artificial intelligence predictive analytics in heart failure: results of the pilot phase of a pragmatic randomized clinical trial | 4.1 | 2 | Citations (PDF) |
| 7 | Contemporary American and European Guidelines for Heart Failure Management | 4.9 | 11 | Citations (PDF) |
| 8 | Contemporary pharmacological treatment and management of heart failure | 12.5 | 15 | Citations (PDF) |
| 9 | Pre-Heart Failure, Heart Stress, and Subclinical Heart Failure | 4.9 | 2 | Citations (PDF) |
| 10 | JACC: Advances Expert Panel Perspective | 1.5 | 1 | Citations (PDF) |
| 11 | Early Uptitration of GDMT Is Associated With More Successful Decongestion and Better Outcomes | 2.6 | 0 | Citations (PDF) |
| 12 | Achieving Equitable Cardiovascular Care for All | 1.5 | 1 | Citations (PDF) |
| 13 | Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation | 4.9 | 118 | Citations (PDF) |
| 14 | Neprilysin Inhibitors in Heart Failure | 3.5 | 50 | Citations (PDF) |
| 15 | Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers | 4.9 | 16 | Citations (PDF) |
| 16 | Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines | 19.4 | 17 | Citations (PDF) |
| 17 | Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease | 4.9 | 11 | Citations (PDF) |
| 18 | Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization | 4.9 | 27 | Citations (PDF) |
| 19 | Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies | 8.2 | 5 | Citations (PDF) |
| 20 | Cardiac rehabilitation in heart failure: Indications for exercise training based on heart failure phenotype | 5.9 | 4 | Citations (PDF) |
| 21 | Sex Differences in Heart Failure | 1.3 | 93 | Citations (PDF) |
| 22 | The year in cardiovascular medicine 2021: heart failure and cardiomyopathies | 2.2 | 15 | Citations (PDF) |
| 23 | Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap | 0.7 | 26 | Citations (PDF) |
| 24 | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases | 2.6 | 36 | Citations (PDF) |
| 25 | On the Shoulders of Witnesses: A Conversation With Biykem Bozkurt, MD, PhD | 19.4 | 0 | Citations (PDF) |
| 26 | Women leaders: transforming the culture in cardiology | 2.5 | 5 | Citations (PDF) |
| 27 | Sixth Annual Go Red for Women Issue | 19.4 | 3 | Citations (PDF) |
| 28 | An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps | 2.2 | 4 | Citations (PDF) |
| 29 | 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play | 2.6 | 269 | Citations (PDF) |
| 30 | 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary | 1.3 | 64 | Citations (PDF) |
| 31 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary | 2.6 | 502 | Citations (PDF) |
| 32 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | 19.4 | 1,143 | Citations (PDF) |
| 33 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | 19.4 | 204 | Citations (PDF) |
| 34 | Telehealth in Heart Failure | 2.3 | 5 | Citations (PDF) |
| 35 | 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure | 2.6 | 1,239 | Citations (PDF) |
| 36 | The year in cardiovascular medicine 2021: heart failure and cardiomyopathies | 0.0 | 1 | Citations (PDF) |
| 37 | Outcomes and Resource Utilization in Patients Hospitalized with Gastrointestinal Bleeding Complicated by Types 1 and 2 Myocardial Infarction | 2.1 | 4 | Citations (PDF) |
| 38 | Outcomes of Hospitalizations With Septic Shock Complicated by Types 1 and 2 Myocardial Infarction | 1.9 | 1 | Citations (PDF) |
| 39 | 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards | 4.5 | 6 | Citations (PDF) |
| 40 | Programmable Bio-NanoChip Technology for the Diagnosis of Cardiovascular
Disease at the Point of Care | 1.7 | 13 | Citations (PDF) |
| 41 | Peripartum Cardiomyopathy: A Contemporary Review | 1.7 | 6 | Citations (PDF) |
| 42 | The Treatment of Heart Failure in the 21st Century: Is the Glass Half
Empty or Half Full? | 1.7 | 2 | Citations (PDF) |
| 43 | Redefining Myocardial Infarction: What is new in the ESC/ACCF/AHA/WHF
Third Universal Definition of Myocardial Infarction? | 1.7 | 10 | Citations (PDF) |
| 44 | Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events | 2.6 | 38 | Citations (PDF) |
| 45 | Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan | 2.3 | 1 | Citations (PDF) |
| 46 | Fifth Annual Go Red for Women Issue | 19.4 | 1 | Citations (PDF) |
| 47 | Cardiac Rehabilitation for Patients With Heart Failure | 2.6 | 159 | Citations (PDF) |
| 48 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure | 8.2 | 844 | Citations (PDF) |
| 49 | 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) | 4.5 | 82 | Citations (PDF) |
| 50 | Universal Definition and Classification of Heart Failure | 1.3 | 477 | Citations (PDF) |
| 51 | Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy | 8.2 | 133 | Citations (PDF) |
| 52 | Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United States | 2.1 | 10 | Citations (PDF) |
| 53 | Ending Gender Inequality in Cardiovascular Clinical Trial Leadership | 2.6 | 56 | Citations (PDF) |
| 54 | Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy | 1.3 | 39 | Citations (PDF) |
| 55 | Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association | 19.4 | 594 | Citations (PDF) |
| 56 | Myocarditis With COVID-19 mRNA Vaccines | 19.4 | 661 | Citations (PDF) |
| 57 | Public perception of heart failure on twitter: A sentiment analysis | 5.9 | 2 | Citations (PDF) |
| 58 | 2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure | 2.9 | 47 | Citations (PDF) |
| 59 | Proinflammatory TH17 cytokine activation, disease severity and outcomes in peripartum cardiomyopathy | 2.2 | 6 | Citations (PDF) |
| 60 | Heart Failure in Women | 1.7 | 89 | Citations (PDF) |
| 61 | Heart Failure as a Consequence of Dilated Cardiomyopathy 2020, , 269-287.e2 | | 1 | Citations (PDF) |
| 62 | Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System | 7.0 | 43 | Citations (PDF) |
| 63 | President's Message | 1.3 | 0 | Citations (PDF) |
| 64 | Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction | 2.1 | 40 | Citations (PDF) |
| 65 | Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 | 1.3 | 307 | Citations (PDF) |
| 66 | Cardiac Surgery During the Coronavirus Disease 2019 Pandemic: Perioperative Considerations and Triage Recommendations | 4.3 | 64 | Citations (PDF) |
| 67 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 2.2 | 64 | Citations (PDF) |
| 68 | Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization | 4.8 | 189 | Citations (PDF) |
| 69 | Fourth Annual Go Red for Women Issue | 19.4 | 2 | Citations (PDF) |
| 70 | Factor Xa Inhibition, A New Strategy for Prevention of Adverse Cardiac Remodeling in Early Stages? | 3.5 | 3 | Citations (PDF) |
| 71 | Substance and Substrate | 19.4 | 16 | Citations (PDF) |
| 72 | Endpoints in Heart Failure Drug Development | 4.9 | 39 | Citations (PDF) |
| 73 | Evaluation for Heart Transplantation and LVAD Implantation | 2.6 | 101 | Citations (PDF) |
| 74 | Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome | 19.4 | 454 | Citations (PDF) |
| 75 | Myocarditis and inflammatory cardiomyopathy: current evidence and future directions | 12.5 | 705 | Citations (PDF) |
| 76 | 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | 19.4 | 590 | Citations (PDF) |
| 77 | 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary | 2.6 | 522 | Citations (PDF) |
| 78 | 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease | 2.6 | 670 | Citations (PDF) |
| 79 | Heart Failure Site-Based Research in the United States | 4.9 | 7 | Citations (PDF) |
| 80 | 2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography | 4.2 | 9 | Citations (PDF) |
| 81 | Differences between Academic and Non-Academic Institutions in Heart Failure Clinical Trials in North America: Insights from the HFSA Research Network Survey | 1.3 | 0 | Citations (PDF) |
| 82 | 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure | 2.6 | 250 | Citations (PDF) |
| 83 | Enkephalins and the Opioid System of the Heart | 4.8 | 6 | Citations (PDF) |
| 84 | Breastfeeding, Cellular Immune Activation, and Myocardial Recovery in Peripartum Cardiomyopathy | 3.5 | 27 | Citations (PDF) |
| 85 | Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure | 2.6 | 35 | Citations (PDF) |
| 86 | Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference | 5.6 | 272 | Citations (PDF) |
| 87 | Third Annual Go Red for Women Issue | 19.4 | 1 | Citations (PDF) |
| 88 | Target Dose Versus Maximum Tolerated Dose in Heart Failure | 4.9 | 8 | Citations (PDF) |
| 89 | Impact of a Resident-Centered Interprofessional Quality Improvement Intervention on Acute Care Length of Stay | 1.2 | 2 | Citations (PDF) |
| 90 | Venoarterial ECMO for Adults | 2.6 | 338 | Citations (PDF) |
| 91 | Update in recent clinical trials in heart failure | 1.8 | 2 | Citations (PDF) |
| 92 | Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy | 1.8 | 16 | Citations (PDF) |
| 93 | 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | 19.4 | 251 | Citations (PDF) |
| 94 | What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines | 3.1 | 29 | Citations (PDF) |
| 95 | Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | 19.4 | 569 | Citations (PDF) |
| 96 | The 2017 AHA/ACC Performance and Quality Measures for Patients With Acute Myocardial Infarction | 9.7 | 2 | Citations (PDF) |
| 97 | Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study | 1.3 | 15 | Citations (PDF) |
| 98 | Lifestyle Modifications for Preventing and Treating Heart Failure | 2.6 | 115 | Citations (PDF) |
| 99 | High‐Sensitivity Cardiac Troponin: From Patient Phenotypes to Clinical Events in Patients With Heart Failure With Preserved Ejection Fraction | 4.3 | 2 | Citations (PDF) |
| 100 | Heart Failure Society of America Research Network Survey | 1.3 | 0 | Citations (PDF) |
| 101 | American Heart Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations | 4.3 | 21 | Citations (PDF) |
| 102 | Dilated Cardiomyopathy 2018, , 202-208 | | 1 | Citations (PDF) |
| 103 | Heart Failure 2018, , 241-252 | | 1 | Citations (PDF) |
| 104 | Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry | 4.3 | 24 | Citations (PDF) |
| 105 | Myocardial Injury, Obesity, and the Obesity Paradox | 4.9 | 19 | Citations (PDF) |
| 106 | Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study | 2.1 | 19 | Citations (PDF) |
| 107 | BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study | 2.2 | 41 | Citations (PDF) |
| 108 | 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary | 2.5 | 169 | Citations (PDF) |
| 109 | Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association | 19.4 | 428 | Citations (PDF) |
| 110 | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure | 1.3 | 526 | Citations (PDF) |
| 111 | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America | 19.4 | 2,170 | Citations (PDF) |
| 112 | Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine | 1.9 | 19 | Citations (PDF) |
| 113 | Acoustic Detection of Coronary Occlusions before and after Stent Placement Using an Electronic Stethoscope | 2.1 | 9 | Citations (PDF) |
| 114 | 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure | 1.3 | 56 | Citations (PDF) |
| 115 | 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America | 19.4 | 478 | Citations (PDF) |
| 116 | 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure | 2.6 | 540 | Citations (PDF) |
| 117 | Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System | 19.4 | 188 | Citations (PDF) |
| 118 | 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease | 2.9 | 243 | Citations (PDF) |
| 119 | 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST‐elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST‐elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions | 1.8 | 86 | Citations (PDF) |
| 120 | Usefulness of the Sum of Pulmonary Capillary Wedge Pressure and Right Atrial Pressure as a Congestion Index that Prognosticates Heart Failure Survival (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial) | 1.9 | 22 | Citations (PDF) |
| 121 | Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association | 19.4 | 334 | Citations (PDF) |
| 122 | Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association | 19.4 | 583 | Citations (PDF) |
| 123 | Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG‐CAD) Registry | 4.3 | 16 | Citations (PDF) |
| 124 | The Assessment of Stent Effectiveness Using a Wearable Beamforming MEMS Microphone Array System | 5.3 | 4 | Citations (PDF) |
| 125 | Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System | 2.6 | 162 | Citations (PDF) |
| 126 | Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves | 19.4 | 110 | Citations (PDF) |
| 127 | Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease | 8.8 | 34 | Citations (PDF) |
| 128 | Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy | 4.9 | 72 | Citations (PDF) |
| 129 | Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T | 4.4 | 2 | Citations (PDF) |
| 130 | Diagnosis and management of acute heart failure | 1.2 | 24 | Citations (PDF) |
| 131 | Heart Failure, Introduction 2015, , 3-20 | | 0 | Citations (PDF) |
| 132 | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials | 19.4 | 380 | Citations (PDF) |
| 133 | No Increase in Mortality Seen with β-blocker Treatment in Heart Failure Patients with Cocaine Use | 1.3 | 0 | Citations (PDF) |
| 134 | 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease | 2.9 | 107 | Citations (PDF) |
| 135 | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials | 2.6 | 458 | Citations (PDF) |
| 136 | 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials | 1.6 | 45 | Citations (PDF) |
| 137 | Provider Type and Quality of Outpatient Cardiovascular Disease Care | 2.6 | 53 | Citations (PDF) |
| 138 | High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories | 7.0 | 36 | Citations (PDF) |
| 139 | Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease | 1.9 | 153 | Citations (PDF) |
| 140 | Heart Failure Evaluation and Long-Term Management 2014, , 172-184 | | 0 | Citations (PDF) |
| 141 | Update: Shortness of Breath | 19.4 | 1 | Citations (PDF) |
| 142 | Chagas Cardiomyopathy is Associated With Higher Incidence of Stroke: A Meta-analysis of Observational Studies | 1.3 | 38 | Citations (PDF) |
| 143 | Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure | 2.6 | 82 | Citations (PDF) |
| 144 | 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery | 19.4 | 831 | Citations (PDF) |
| 145 | 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary | 19.4 | 646 | Citations (PDF) |
| 146 | The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey | 19.4 | 120 | Citations (PDF) |
| 147 | 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults | 19.4 | 2,177 | Citations (PDF) |
| 148 | ACC/AHA 2013 Methodology for Developing Clinical Data Standards: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards | 19.4 | 19 | Citations (PDF) |
| 149 | Prognostic Significance of Hyponatremia Among Ambulatory Patients With Heart Failure and Preserved and Reduced Ejection Fractions | 1.9 | 60 | Citations (PDF) |
| 150 | ACC/AHA 2013 Methodology for Developing Clinical Data Standards | 2.6 | 29 | Citations (PDF) |
| 151 | 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary | 2.6 | 89 | Citations (PDF) |
| 152 | Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension | 4.9 | 59 | Citations (PDF) |
| 153 | 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk | 19.4 | 2,869 | Citations (PDF) |
| 154 | 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery | 2.6 | 1,141 | Citations (PDF) |
| 155 | 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults | 19.4 | 4,759 | Citations (PDF) |
| 156 | 2014 AHA/ACC guideline for the management of patients with valvular heart disease | 2.9 | 855 | Citations (PDF) |
| 157 | Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock | 2.2 | 15 | Citations (PDF) |
| 158 | Dilated Cardiomyopathy 2014, , 198-202 | | 0 | Citations (PDF) |
| 159 | 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary | 1.6 | 166 | Citations (PDF) |
| 160 | Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations) | 2.6 | 205 | Citations (PDF) |
| 161 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary | 2.6 | 275 | Citations (PDF) |
| 162 | 2013 ACCF/AHA Guideline for the Management of Heart Failure | 19.4 | 2,256 | Citations (PDF) |
| 163 | Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome | 2.2 | 48 | Citations (PDF) |
| 164 | Worsening renal function is not associated with response to treatment in acute heart failure | 2.2 | 22 | Citations (PDF) |
| 165 | Hyperacute T-waves: Wolff-Parkinson-White Pattern or Acute Coronary Syndrome? | 0.8 | 0 | Citations (PDF) |
| 166 | Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure | 2.2 | 25 | Citations (PDF) |
| 167 | Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) | 2.6 | 422 | Citations (PDF) |
| 168 | 2013 ACCF/AHA Guideline for the Management of Heart Failure | 2.6 | 6,830 | Citations (PDF) |
| 169 | Cardiovascular Function and Treatment in β-Thalassemia Major | 19.4 | 312 | Citations (PDF) |
| 170 | Transcatheter Aortic Valve Replacement as a Treatment for Late Apicoaortic Conduit Obstruction in a Patient With Severe Aortic Stenosis | 19.4 | 7 | Citations (PDF) |
| 171 | Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations) | 19.4 | 157 | Citations (PDF) |
| 172 | Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) | 19.4 | 372 | Citations (PDF) |
| 173 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary | 19.4 | 2,729 | Citations (PDF) |
| 174 | Early Experience of a Transcatheter Aortic Valve Program at a Veterans Affairs Facility | 9.8 | 11 | Citations (PDF) |
| 175 | Percutaneous Coronary Intervention vs. Coronary Artery Bypass Graft Surgery for Unprotected Left Main Coronary Artery Disease in the Drug-Eluting Stents Era | 1.8 | 32 | Citations (PDF) |
| 176 | 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease | 19.4 | 55 | Citations (PDF) |
| 177 | Response to Ryan and Parwani: Heart Failure Patients With Low Blood Pressure: How Should We Manage Neurohormonal Blocking Drugs? | 4.8 | 15 | Citations (PDF) |
| 178 | Delayed recovery in peripartum cardiomyopathy: an indication for long‐term follow‐up and sustained therapy | 8.2 | 92 | Citations (PDF) |
| 179 | Sexual Activity and Cardiovascular Disease | 19.4 | 277 | Citations (PDF) |
| 180 | New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patients—A Matter of Time for Contractility | 1.3 | 24 | Citations (PDF) |
| 181 | Prevalence, Morbidity, and Mortality of Heart Failure–Related Hospitalizations in Children in the United States: A Population-Based Study | 1.3 | 237 | Citations (PDF) |
| 182 | Lower Heart Rate Associated With Improved Outcomes in Heart Failure With Preserved Ejection Fraction | 1.3 | 0 | Citations (PDF) |
| 183 | Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction | 2.6 | 583 | Citations (PDF) |
| 184 | Third Universal Definition of Myocardial Infarction | 2.6 | 2,488 | Citations (PDF) |
| 185 | Establishment of a transcatheter aortic valve program and heart valve team at a Veterans Affairs facility | 2.1 | 10 | Citations (PDF) |
| 186 | Echocardiographic Changes During Treatment of Acute Decompensated Heart Failure: Insights From the ESCAPE Trial | 1.3 | 34 | Citations (PDF) |
| 187 | Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study | 0.0 | 23 | Citations (PDF) |
| 188 | Guiding Left Ventricular Lead Positioning and Refining Ability to Predict Response and Nonresponse to Cardiac Resynchronization Therapy Using dP/dtmax | 2.6 | 2 | Citations (PDF) |
| 189 | Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship | 2.9 | 68 | Citations (PDF) |
| 190 | Barriers to Non-HDL Cholesterol Goal Attainment by Providers | 2.1 | 28 | Citations (PDF) |
| 191 | Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF) | 1.3 | 172 | Citations (PDF) |
| 192 | Lack of Association of Changes in BNP with Cardiorenal Syndrome during Treatment of Acute Decompensated Heart Failure | 1.3 | 0 | Citations (PDF) |
| 193 | Digoxin treatment in heart failure — Unveiling risk by cluster analysis of DIG data | 2.2 | 17 | Citations (PDF) |
| 194 | Heart Failure as a Consequence of Dilated Cardiomyopathy 2011, , 372-394 | | 2 | Citations (PDF) |
| 195 | Trials on the Effect of Cardiac Resynchronization on Arterial Blood Pressure in Patients With Heart Failure | 1.9 | 19 | Citations (PDF) |
| 196 | ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records | 19.4 | 63 | Citations (PDF) |
| 197 | Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure | 4.8 | 153 | Citations (PDF) |
| 198 | Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus | 1.9 | 79 | Citations (PDF) |
| 199 | Digoxin and Other Positive Inotropic Agents 2010, , 171-175 | | 0 | Citations (PDF) |
| 200 | Where Do We Currently Stand With Advice On Hormone Replacement Therapy For Women? | 1.7 | 6 | Citations (PDF) |
| 201 | Randomized Trial of Aldosterone AntagonisM in Diastolic Heart Failure (RAAM-DHF) | 1.3 | 4 | Citations (PDF) |
| 202 | Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure | 1.3 | 1 | Citations (PDF) |
| 203 | Cost of Heart Failure Admissions in Children in the United States | 1.3 | 4 | Citations (PDF) |
| 204 | Heart Failure 2010, , 149-156 | | 0 | Citations (PDF) |
| 205 | Improved propensity matching for heart failure using neural gas and self-organizing maps 2009, , | | 0 | Citations (PDF) |
| 206 | Unsupervised cluster analysis and mortality risk in the Digitalis Investigation Group (DIG) trial of heart failure 2009, , | | 0 | Citations (PDF) |
| 207 | Acute Bacterial Pneumonia is Associated With the Occurrence of Acute Coronary Syndromes | 1.3 | 90 | Citations (PDF) |
| 208 | Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients With Heart Failure | 1.9 | 21 | Citations (PDF) |
| 209 | Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events | 1.3 | 47 | Citations (PDF) |
| 210 | Hemoglobin Drop during Hospitalization Predicts Poor Survival in Anemic Patients with Acute Decompensated Heart Failure | 1.3 | 0 | Citations (PDF) |
| 211 | Cardiac Resynchronization Therapy in Reversing “Decapitated Hypertension” – A Meta-Analysis | 1.3 | 0 | Citations (PDF) |
| 212 | Futility of Digoxin in a Sub-Population of Heart Failure Patients – A Cluster Analysis of DIG Data | 1.3 | 0 | Citations (PDF) |
| 213 | Does the Level of Experience of Residents Affect Outcomes of Coronary Artery Bypass Surgery? | 2.5 | 64 | Citations (PDF) |
| 214 | Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes | 2.6 | 168 | Citations (PDF) |
| 215 | The association between Staphylococcus aureus bacteremia and acute myocardial infarction | 1.7 | 23 | Citations (PDF) |
| 216 | Biomarkers of inflammation in heart failure | 3.6 | 165 | Citations (PDF) |
| 217 | Treatment of patients with heart failure and preserved ejection fraction | 0.6 | 4 | Citations (PDF) |
| 218 | Digoxin and Clinical Outcomes in Systolic Heart Failure Patients on Contemporary Background Heart Failure Therapy | 1.9 | 23 | Citations (PDF) |
| 219 | Effect of the Soluble TNF‐Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability | 2.9 | 23 | Citations (PDF) |
| 220 | The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes | 2.1 | 41 | Citations (PDF) |
| 221 | Does the use of bilateral internal mammary artery grafts impact survival of veterans undergoing coronary artery bypass surgery? | 2.1 | 2 | Citations (PDF) |
| 222 | The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population | 1.3 | 12 | Citations (PDF) |
| 223 | Effect of Digoxin on Clinical Outcomes in Patients on Contemporary Heart Failure Therapy | 1.3 | 0 | Citations (PDF) |
| 224 | Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction | 19.4 | 458 | Citations (PDF) |
| 225 | The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure | 2.6 | 31 | Citations (PDF) |
| 226 | Dilated Cardiomyopathy 2007, , 1233-1259 | | 1 | Citations (PDF) |
| 227 | Biomarkers of Inflammation 2006, , 295-318 | | 0 | Citations (PDF) |
| 228 | Thiazolidinediones Are Not Associated with Increased Risk of Heart Failure Hospitalizations in Ambulatory Patients with Diabetes Mellitus and Heart Failure | 1.3 | 0 | Citations (PDF) |
| 229 | Mechanisms of idiopathic dilated cardiomyopathies | 1.9 | 0 | Citations (PDF) |
| 230 | Comparison of Morbidity in Women Versus Men With Heart Failure and Preserved Ejection Fraction | 1.9 | 81 | Citations (PDF) |
| 231 | Obesity as a prognostic factor in chronic symptomatic heart failure | 2.9 | 75 | Citations (PDF) |
| 232 | Cardiovascular Toxicity With Highly Active Antiretroviral Therapy: Review of Clinical Studies | 3.4 | 34 | Citations (PDF) |
| 233 | Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines | 2.6 | 192 | Citations (PDF) |
| 234 | Shortness of Breath | 19.4 | 15 | Citations (PDF) |
| 235 | Use of Biomarkers in the Management of Heart Failure | 19.4 | 34 | Citations (PDF) |
| 236 | The clinical experience with anti-cytokine therapy in heart failure 2003, , 95-110 | | 0 | Citations (PDF) |
| 237 | New Therapeutics for Chronic Heart Failure | 20.4 | 53 | Citations (PDF) |
| 238 | Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective | 5.6 | 149 | Citations (PDF) |
| 239 | Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 1.3 | 25 | Citations (PDF) |
| 240 | Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure | 1.3 | 95 | Citations (PDF) |
| 241 | Title is missing! | 3.6 | 18 | Citations (PDF) |
| 242 | The Role of Anti-Cytokine Therapy in the Failing Heart | 0.0 | 0 | Citations (PDF) |
| 243 | Intravenous immune globulin in the therapy of peripartum cardiomyopathy | 2.6 | 174 | Citations (PDF) |
| 244 | Cytokines in Heart Failure: Pathogenetic Mechanisms and Potential Treatment | 3.6 | 50 | Citations (PDF) |
| 245 | Medical and surgical therapy for cardiac remodeling | 1.8 | 8 | Citations (PDF) |
| 246 | An overview of tumor necrosis factor α and the failing human heart | 1.8 | 72 | Citations (PDF) |
| 247 | Cardiac remodeling as a consequence and cause of progressive heart failure | 2.1 | 60 | Citations (PDF) |
| 248 | Progressive dehiscence and dynamic compression of an aortic root homograft: Detection and characterization by transesophageal echocardiography | 2.9 | 1 | Citations (PDF) |
| 249 | Basic mechanisms in heart failure: The cytokine hypothesis | 1.3 | 359 | Citations (PDF) |
| 250 | Tumor necrosis factor-? and tumor necrosis factor receptors in human heart failure | 3.6 | 12 | Citations (PDF) |
| 251 | Aldosterone Antagonism in the Pharmacological Management of Chronic Heart Failure 0, , 82-103 | | 0 | Citations (PDF) |
| 252 | Endpoints in Heart Failure Drug Development | 3.8 | 13 | Citations (PDF) |
